XML 48 R31.htm IDEA: XBRL DOCUMENT v3.22.1

Related Parties Transactions (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Related Party Transactions [Abstract]

Schedule of related party transactions

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’)		The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)		Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)		Director of the Company
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)		Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)		Shareholder of the Company
The Jiangs		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst   Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.   Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.   Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.   Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”)		An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan		Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited		An entity 100% owned by Mr. Tsung-Shann Jiang

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’)		The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)		Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)		Director of the Company
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)		Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)		Shareholder of the Company
		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”)		An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan		Entity controlled by controlling beneficiary shareholder of ABVC

Schedule of accounts receivable due from related parties

		March 31,				December 31,
		2022				2021
GenePharm Inc.		$	142,225			$	142,225
Rgene			2,374				2,374
Amkey			800				800
Total		$	145,399			$	145,399

		December 31,				December 31,
		2021				2020
GenePharm Inc.		$	142,225			$	142,225
Rgene			2,374				-
Amkey			800				1,210
Total		$	145,399			$	143,435

Schedule of amount due from related parties

		March 31,				December 31,
		2022				2021
Rgene		$	48,586			$	49,110
BioFirst			1,563,233				468,435
BioFirst (Australia)			830,118				491,816
BioHopeKing Corporation			121,153				124,972
LBG USA			675				675
BioLite Japan			150,000				150,000
Keypoint			1,610				1,610
Total		$	2,715,375			$	1,286,618

		December 31,				December 31,
		2021				2020
Rgene		$	49,110			$	42,911
AsiaGene			-				4,241
BioFirst			468,435				-
BioFirst (Australia)			491,816				373,235
BioHopeKing Corporation			124,972				123,583
LBG USA			675				675
BioLite Japan			150,000				150,000
Keypoint			1,610				1,610
Total		$	1,286,618			$	696,255

Schedule of amount due to related parties

		March 31,				December 31,
		2022				2021
BioFirst Corporation		$	40,878			$	40,878
BioFirst (Australia)			190,913				132,443
AsiaGene			24,017				24,017
YuanGene			9,205				9,205
The Jiangs			18,750				18,750
Due to shareholders			162,634				168,131
Total		$	446,397			$	393,424

		December 31,				December 31,
		2021				2020
BioFirst Corporation		$	40,878			$	23,647
BioFirst (Australia)			132,443				-
AsiaGene			24,017				-
YuanGene			9,205				9,205
The Jiangs			18,750				16,627
Due to shareholders			168,131				166,261
Due to employee			-				72,705
Total		$	393,424			$	288,445

X

- References

No definition available.

+ Details

Name:	abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of related party transactions. Amount due to related party.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration